Given LINC01257’s correlation with poor survival, its highly specific expression in t(8;21) AML cells, its absence in stromal and bone marrow progenitor cells, as well as its effect on leukemia cell survival, we decided to develop a new therapeutic model to treat pediatric t(8;21) AML through silencing LINC01257. Here, LINC01257 is linked to leukemia.